Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance

NCT05704621 is registered in ClinicalTrials.gov with Korea University Guro Hospital as lead sponsor.

NCT NCT05704621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05704621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance
Lead sponsor
Korea University Guro Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
December 1, 2023
Completion date
December 28, 2028
Enrollment
124 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug related neoplasm/cancer, ovarian cancer